RX Biosyent Inc

BioSyent Inc. ("BioSyent") (TSX VENTURE: RX) today voluntarily initiated a recall of all lots of the Ciprofloxacin Injection 2 mg/mL (Intravenous Infusion) as a precautionary measure. There are currently no reports in Canada of any adverse reactions or adverse events as a result of the administration of Ciprofloxacin Injection to a patient.

This product was manufactured by Claris Lifesciences Limited ("Claris") and therefore the product will bear both the BioSyent Pharma Inc. and Claris Lifesciences Limited names on the product and packaging.

This precautionary recall is being undertaken due to complaints in the United States on certain other medications manufactured by Claris which have subsequently been recalled. Claris has voluntarily extended this recall to include Ciprofloxacin Injection in the United States.

BioSyent Inc. continues to concentrate on its pharmaceutical strategy to source products that have been successfully developed and proven to be safe and effective; manage these products through the regulatory process and product registration (approval); and once approved, market these products in Canada. These pharmaceuticals will compete in both the branded and generic market segments and will not require further product development investment other than regulatory costs.

BioSyent Inc. is a publicly traded specialty pharmaceutical company whose wholly owned subsidiary, BioSyent Pharma Inc., sources, acquires or in-licences pharmaceutical products and markets these products in Canada. Wholly owned BioSyent subsidiary Hedley Technologies Ltd. operates the company's legacy business marketing bio and health friendly non-chemical insecticides. BioSyent common shares are listed for trading on the TSX Venture Exchange (TSXV) under the symbol RX.

This press release may contain information or statements that are forward-looking. The contents herein represent our judgment, as at the release date, and are subject to risks and uncertainties that may cause actual results or outcomes to be materially different from the forward-looking information or statements. Potential risks may include, but are not limited to, those associated with clinical trials, product development, future revenue, operations, profitability and obtaining regulatory approvals.

The TSX Venture Exchange assumes no responsibility for the accuracy of this release and neither approves nor disapproves of the same.

Contacts: BioSyent Inc. Rene C. Goehrum President and CEO (905) 206-0013 (905) 206-1413 (FAX) www.biosyent.com